Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,700.00

Eli Lilly and Company (NYSE:LLY) had its target price increased by research analysts at Jefferies Financial Group from $1,610.00 to $1,700.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group‘s price objective indicates a potential upside of 20.29% from the company’s current price.

LLY has been the subject of several other reports. Weiss Ratings downgraded shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, October 30th. Morgan Stanley upped their target price on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Sanford C. Bernstein reiterated an “outperform” rating and set a $1,450.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 26th. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective on the stock in a report on Tuesday, September 15th. Finally, TD Cowen reissued a “buy” rating and set a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $59.22 during trading on Monday, hitting $1,413.22. The company had a trading volume of 3,760,490 shares, compared to its average volume of 2,967,246. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm has a market capitalization of $1.33 trillion, a P/E ratio of 45.87, a price-to-earnings-growth ratio of 1.62 and a beta of 0.40. The stock has a 50 day simple moving average of $1,215.24 and a 200 day simple moving average of $1,101.16.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the firm earned $7.02 EPS. The business’s revenue was up 38.6% on a year-over-year basis. As a group, analysts anticipate that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by insiders.

Institutional Trading of Eli Lilly and Company

Large investors have recently made changes to their positions in the stock. Integrity Financial Corp WA boosted its stake in shares of Eli Lilly and Company by 1.3% in the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after purchasing an additional 8 shares during the period. LCM Capital Management Inc raised its holdings in Eli Lilly and Company by 3.3% in the third quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock valued at $293,000 after acquiring an additional 8 shares in the last quarter. Smith Shellnut Wilson LLC ADV boosted its stake in Eli Lilly and Company by 4.1% during the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock valued at $235,000 after acquiring an additional 8 shares during the last quarter. Financial Network Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 5.6% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company’s stock worth $175,000 after acquiring an additional 8 shares in the last quarter. Finally, Eads & Heald Wealth Management increased its position in shares of Eli Lilly and Company by 0.5% in the 3rd quarter. Eads & Heald Wealth Management now owns 1,469 shares of the company’s stock worth $1,700,000 after purchasing an additional 8 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo reduced sleep-apnea breathing interruptions by up to an average of 44% after 52 weeks; up to 32% of participants achieved remission or mild disease. Lilly also reported improvements in oxygen-related measures and plans to seek FDA approval for obstructive sleep apnea by year-end 2026. A new indication could broaden the pill’s commercial opportunity beyond weight loss. Reuters article
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610, adding to the positive reaction to the trial results. Yahoo Finance article
• Positive Sentiment: Lilly’s agreements with Hims & Hers and LifeMD will offer eligible U.S. adults digital access to branded Zepbound and Foundayo through telehealth and prescription fulfillment, potentially widening the company’s reach. Yahoo Finance article
• Negative Sentiment: The FDA issued a warning about a potential increased risk of a serious eye condition associated with GLP-1 medicines, including weight-loss drugs. The safety alert could weigh on sentiment toward Lilly’s class of treatments, though the provided report does not quantify any effect on use or sales. Reuters article

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.